Recordati Industria Chimica e Farmaceutica SPAAz. Post raggruppamento Aktie
| 52,10EUR | -1,05EUR | -1,98% |
WKN DE: A0EABR / ISIN: IT0003828271
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 4 362 | 4 303 | 4 369 | 4 455 | 4 583 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,33 | 0,37 | 0,42 | 0,47 | 0,51 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 773 | 850 | 1 174 | 1 202 | 1 491 |
| Summe Anlagevermögen | 2 337 | 2 374 | 3 263 | 3 495 | 4 346 |
| Summe Aktiva | 2 712 | 2 816 | 3 999 | 4 208 | 5 134 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 1 061 | 992 | 1 717 | 1 809 | 2 484 |
| Summe Fremdkapital | 1 435 | 1 435 | 2 453 | 2 522 | 3 273 |
| Summe Eigenkapital | 1 276 | 1 382 | 1 546 | 1 686 | 1 861 |
| Summe Passiva | 2 712 | 2 816 | 3 999 | 4 208 | 5 134 |
Adresse
| Via Matteo Civitali, 1, 20148 Milan | |
| Telefon | +39 (02) 48787-1 |
| Fax | +39 (02) 40073-747 |
| Internet | http://www.recordati.it/ |
Management
|
Andrea Recordati
Chairman |
|
Bibianne Bon
Group Chief Legal Officer |
|
Cathrin Petty
Executive Director |
|
Elisa Corghi
Independent Director |
|
Ezio Maria Simonelli
Principal |
|
Federica de Medici
Director-Investor Relations & Communications |
|
Gabriele Finzi
Executive VP-Corporate Development & Licensing |
|
Giampiero Mazza
Executive Director |
|
Giorgio De Palma
Executive Director |
|
Giovanni Minora
Head-Group Audit |
|
Giuseppe Gualazzini
Senior Vice President-Group Human Resources |
|
Guido Guidi
Vice Chairman |
|
Joanna Susan Le Couilliard
Independent Non-Executive Director |
|
Kim Stratton
Non-Executive Director |
|
Luigi Felice la Corte
Group Chief Financial Officer & Executive Director |
|
Maria Lamelas Godinez
Director-People Engagement & Change Management |
|
Michaela Castelli
Lead Independent Non-Executive Director |
|
Piergiorgio Peluso
Independent Non-Executive Director |
|
Raffaele Sabia
Senior VP-Pharmaceutical Research & Development |
|
Robert Koremans
Chief Executive Officer & Director |
|
Roberto Teruzzi
Executive VP-Group Industrial Operations |
|
Silvia Signoretti
Secretary & Group Corporate Law Counsel |
|
Witold Urban
VP-Central & Eastern Europe Region |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
